Eike Steinmann

Dr. Eike Steinmann

Head of the Department for Molecular & Medical Virology, Leibniz University, Bochum, Germany

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Journal of Hospital Infection
Verified
Journal Article
Closed access
Günter KampfGünter Kampf
Günter Kampf
Daniel TodtDaniel Todt
Daniel Todt
SPStephanie Pfaender
Stephanie Pfaender
ESEike Steinmann
Eike Steinmann

9 May 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TPThomas Pietschmann
Thomas Pietschmann
AKArtur Kaul
Artur Kaul
GKGeorge Koutsoudakis
George Koutsoudakis
ASAnna Shavinskaya
Anna Shavinskaya
SKStephanie Kallis
Stephanie Kallis
RBRalf Bartenschlager
Ralf Bartenschlager
Chronic liver disease caused by infection with hepatitis C virus (HCV) is an important global health problem that currently affects 170 million people. A major impediment in HCV research and drug development has been the lack of culture systems supporting virus production. This obstacle was recently overcome by using JFH1-based full-length genomes that allow production of viruses infectious both in vitro and in vivo . Although this improvement was important, because of the restriction to the JFH1 isolate and a single chimera consisting of J6CF and JFH1-derived sequences, broadly based comparative studies between different HCV strains were not possible. Therefore, in this study we created a series of further chimeric genomes allowing production of infectious genotype (GT) 1a, 1b, 2a, and 3a particles. With the exception of the GT3a/JFH1 chimera, efficient virus production was obtained when the genome fragments were fused via a site located right after the first transmembrane domain of NS2. The most efficient construct is a GT2a/2a chimera consisting of J6CF- and JFH1-derived sequences connected via this junction. This hybrid, designated Jc1, yielded infectious titers 100– to 1,000-fold higher than the parental isolate and all other chimeras, suggesting that determinants within the structural proteins govern kinetic and efficiency of virus assembly and release. Finally, we describe an E1-specific antiserum capable of neutralizing infectivity of all HCV chimeras.

16 October 2012 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
JSJ Steinmann
J Steinmann
JBJan Buer
Jan Buer
TPThomas Pietschmann
Thomas Pietschmann
ESEike Steinmann
Eike Steinmann
The consumption of green tea (Camellia sinensis) has been shown to have many physiological and pharmacological health benefits. In the past two decades several studies have reported that epigallocatechin‐3‐gallate (EGCG), the main constituent of green tea, has anti‐infective properties. Antiviral activities of EGCG with different modes of action have been demonstrated on diverse families of viruses, such as Retroviridae, Orthomyxoviridae and Flaviviridae and include important human pathogens like human immunodeficiency virus, influenza A virus and the hepatitis C virus. Furthermore, the molecule interferes with the replication cycle of DNA viruses like hepatitis B virus, herpes simplex virus and adenovirus. Most of these studies demonstrated antiviral properties within physiological concentrations of EGCG in vitro. In contrast, the minimum inhibitory concentrations against bacteria were 10–100‐fold higher. Nevertheless, the antibacterial effects of EGCG alone and in combination with different antibiotics have been intensively analysed against a number of bacteria including multidrug‐resistant strains such as methicillin‐resistant Staphylococcus aureus or Stenotrophomonas maltophilia. Furthermore, the catechin EGCG has antifungal activity against human‐pathogenic yeasts like Candida albicans. Although the mechanistic effects of EGCG are not fully understood, there are results indicating that EGCG binds to lipid membranes and affects the folic acid metabolism of bacteria and fungi by inhibiting the cytoplasmic enzyme dihydrofolate reductase. This review summarizes the current knowledge and future perspectives on the antibacterial, antifungal and antiviral effects of the green tea constituent EGCG.

1 June 2006 in Journal of Virology
Verified
Journal Article
Closed access
GKGeorge Koutsoudakis
George Koutsoudakis
AKArtur Kaul
Artur Kaul
ESEike Steinmann
Eike Steinmann
SKStephanie Kallis
Stephanie Kallis
Volker LohmannVolker Lohmann
Volker Lohmann
RBRalf Bartenschlager
Ralf Bartenschlager
The lack of an efficient system to produce hepatitis C virus (HCV) particles has impeded the analysis of the HCV life cycle. Recently, we along with others demonstrated that transfection of Huh7 hepatoma cells with a novel HCV isolate (JFH1) yields infectious viruses. To facilitate studies of HCV replication, we generated JFH1-based bicistronic luciferase reporter virus genomes. We found that RNA replication of the reporter construct was only slightly attenuated and that virus titers produced were only three- to fivefold lower compared to the parental virus, making these reporter viruses an ideal tool for quantitative analyses of HCV infections. To expand the scope of the system, we created two chimeric JFH1 luciferase reporter viruses with structural proteins from the Con1 (genotype 1b) and J6CF (genotype 2a) strains. Using these and the authentic JFH1 reporter viruses, we analyzed the early steps of the HCV life cycle. Our data show that the mode of virus entry is conserved between these isolates and involves CD81 as a key receptor for pH-dependent virus entry. Competition studies and time course experiments suggest that interactions of HCV with cell surface-resident glycosaminoglycans aid in efficient infection of Huh7 cells and that CD81 acts during a postattachment step. The reporter viruses described here should be instrumental for investigating the viral life cycle and for the development of HCV inhibitors.

20 July 2007 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
ESEike Steinmann
Eike Steinmann
FPFrancois Penin
Francois Penin
SKStephanie Kallis
Stephanie Kallis
APArvind H Patel
Arvind H Patel
RBRalf Bartenschlager
Ralf Bartenschlager
TPThomas Pietschmann
Thomas Pietschmann
Hepatitis C virus (HCV) infection is associated with chronic liver disease and currently affects about 3% of the world population. Although much has been learned about the function of individual viral proteins, the role of the HCV p7 protein in virus replication is not known. Recent data, however, suggest that it forms ion channels that may be targeted by antiviral compounds. Moreover, this protein was shown to be essential for infectivity in chimpanzee. Employing the novel HCV infection system and using a genetic approach to investigate the function of p7 in the viral replication cycle, we find that this protein is essential for efficient assembly and release of infectious virions across divergent virus strains. We show that p7 promotes virus particle production in a genotype-specific manner most likely due to interactions with other viral factors. Virus entry, on the other hand, is largely independent of p7, as the specific infectivity of released virions with a defect in p7 was not affected. Together, these observations indicate that p7 is primarily involved in the late phase of the HCV replication cycle. Finally, we note that p7 variants from different isolates deviate substantially in their capacity to promote virus production, suggesting that p7 is an important virulence factor that may modulate fitness and in turn virus persistence and pathogenesis. The hepatitis C virus (HCV), a major human pathogen associated with severe liver disease, encodes a small membrane protein designated p7. Although recent reports indicated that p7 forms channels conducting ions across membranes and is essential for HCV infection, its exact role in the viral life cycle remained elusive. In this study, we illustrate that HCV relies on p7 function for efficient assembly and release of infectious progeny virions from liver cells. Conversely, entry of HCV particles into new host cells is independent of p7. This new evidence supports the recent proposal to include p7 into the family of viroporins that comprises proteins from diverse viruses, for instance, HIV-1 and influenza A virus. Members of this group of functionally related proteins form membrane pores that promote virus release and in some cases also virus entry. Moreover, we identify several conserved p7 residues crucial for functioning of this protein. These amino acids possibly stabilize the structure of p7 or directly participate in channelling of ions. Interestingly, p7 variants from divergent patient isolates differ with regard to their ability to promote virus production, suggesting that p7 modulates viral fitness. Together these observations shed new light on fundamental aspects of the HCV replication strategy.

1 July 2020 in Emerging Infectious Diseases
Verified
Journal Article
Open access
PDF file
AKAnnika Kratzel
Annika Kratzel
Daniel TodtDaniel Todt
Daniel Todt
PVPhilip V'kovski
Philip V'kovski
SSSilvio Steiner
Silvio Steiner
MGMitra Gultom
Mitra Gultom
SPStephanie Pfaender
Stephanie Pfaender
Inactivation of SARS-CoV-2 by Hand Rub Formulations